Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MM-302 + trastuzumab
- Development stage
- Discontinued
- Lead developer
- Merrimack Pharmaceuticals
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MM-302 + trastuzumab is a combination therapy for HER2-positive advanced or metastatic breast cancer. MM-302 is a HER2-targeted antibody–liposomal doxorubicin conjugate, designed to deliver the chemotherapeutic agent doxorubicin specifically to HER2-overexpressing tumor cells while limiting exposure to healthy tissues such as cardiomyocytes. Trastuzumab is a monoclonal antibody that binds to the extracellular domain of the HER2 receptor, inhibiting its signaling and mediating immune responses against tumor cells. The combination aims to enhance antitumor efficacy by targeting different epitopes on the HER2 receptor and has been evaluated in clinical trials for patients with refractory or previously treated HER2-positive breast cancer[1][2][3][5].
- Brand names
- Herceptin
- Other names
- nano-doxorubicin (for MM-302)
02
Targets
DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on MM-302 + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MM-302 + trastuzumab.